JP2021167324A5 - - Google Patents

Download PDF

Info

Publication number
JP2021167324A5
JP2021167324A5 JP2021103895A JP2021103895A JP2021167324A5 JP 2021167324 A5 JP2021167324 A5 JP 2021167324A5 JP 2021103895 A JP2021103895 A JP 2021103895A JP 2021103895 A JP2021103895 A JP 2021103895A JP 2021167324 A5 JP2021167324 A5 JP 2021167324A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
molecule
composition according
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021103895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021167324A (ja
Filing date
Publication date
Priority claimed from JP2017563600A external-priority patent/JP2018516950A/ja
Application filed filed Critical
Publication of JP2021167324A publication Critical patent/JP2021167324A/ja
Publication of JP2021167324A5 publication Critical patent/JP2021167324A5/ja
Pending legal-status Critical Current

Links

JP2021103895A 2015-06-12 2021-06-23 がん治療のための集中インターフェロン免疫療法 Pending JP2021167324A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562175044P 2015-06-12 2015-06-12
US201562175024P 2015-06-12 2015-06-12
US62/175,024 2015-06-12
US62/175,044 2015-06-12
US201562257852P 2015-11-20 2015-11-20
US62/257,852 2015-11-20
US201662321724P 2016-04-12 2016-04-12
US62/321,724 2016-04-12
JP2017563600A JP2018516950A (ja) 2015-06-12 2016-06-10 がん治療のための集中インターフェロン免疫療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017563600A Division JP2018516950A (ja) 2015-06-12 2016-06-10 がん治療のための集中インターフェロン免疫療法

Publications (2)

Publication Number Publication Date
JP2021167324A JP2021167324A (ja) 2021-10-21
JP2021167324A5 true JP2021167324A5 (https=) 2021-12-23

Family

ID=57504236

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017563600A Pending JP2018516950A (ja) 2015-06-12 2016-06-10 がん治療のための集中インターフェロン免疫療法
JP2021103895A Pending JP2021167324A (ja) 2015-06-12 2021-06-23 がん治療のための集中インターフェロン免疫療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017563600A Pending JP2018516950A (ja) 2015-06-12 2016-06-10 がん治療のための集中インターフェロン免疫療法

Country Status (6)

Country Link
US (1) US20180312561A1 (https=)
EP (1) EP3307301A4 (https=)
JP (2) JP2018516950A (https=)
AU (2) AU2016274897B2 (https=)
CA (1) CA2988619A1 (https=)
WO (1) WO2016201251A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
EP3577133A1 (en) * 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
CN109810995B (zh) * 2017-12-06 2020-10-02 阿思科力(苏州)生物科技有限公司 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
CN110194800B (zh) * 2018-02-26 2022-11-18 张灏 一种融合蛋白、细胞外泌体和肿瘤疫苗及其应用
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
KR20220109436A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 인터페론-결합된 항원 결합 단백질 및 이의 용도
CA3222185A1 (en) * 2021-06-03 2022-12-08 Orum Therapeutics, Inc. Neodegrader-anti-cd33 antibody conjugates
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
US9272029B2 (en) * 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
ES2611479T3 (es) * 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
EP2718457A4 (en) * 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
SG10201603411WA (en) * 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
ES2800426T3 (es) * 2012-03-03 2020-12-30 Immungene Inc Moléculas de fusión anticuerpos-mutante de interferón modificadas
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease

Similar Documents

Publication Publication Date Title
JP2021167324A5 (https=)
US11987635B2 (en) Anti-4-1BB antibodies and methods of making and using thereof
CN107428832B (zh) 抗pd-l1抗体
JP6743320B1 (ja) 抗ｃｄ１３７抗体
CN106573977B (zh) 针对ceacam1的人源化抗体
JP2020515247A5 (https=)
JP2019511212A (ja) ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体
US20180044428A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
JP2018516950A5 (https=)
KR20190117493A (ko) 항 pd-1 항체 및 그의 용도
JP7606706B2 (ja) ヒトネクチン－２に特異的な抗体
JP7809635B2 (ja) Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
WO2019206095A1 (zh) 针对tim-3的抗体及其用途
WO2023166210A1 (en) Anti pd-l2 antibody
EP4263584A1 (en) Combination therapy for the treatment of cancer
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
EP3893888A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
CN111655725A (zh) 用于治疗癌症的组合产品
JP2022513246A (ja) 抗ｃｅａｃａｍ６及びｔｉｍ３抗体の医薬組み合わせ
JP2022513036A (ja) がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ
WO2023146394A1 (en) Combination therapy for the treatment of cancer
TW202400662A (zh) 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途
JP7684656B2 (ja) 免疫抑制剤
US20200148758A1 (en) Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof
US20260008861A9 (en) Anti-4-1bb antibodies and methods of making and using thereof